Market Cap 2.40B
Revenue (ttm) 109.79M
Net Income (ttm) -153.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -139.80%
Debt to Equity Ratio -1.43
Volume 823,700
Avg Vol 809,880
Day's Range N/A - N/A
Shares Out 48.88M
Stochastic %K 83%
Beta 1.57
Analysts Strong Sell
Price Target $59.50

Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 768 9780
Address:
400 Alexander Park Drive, 4th Floor, Princeton, United States
ivocsev
ivocsev Aug. 18 at 11:51 AM
1 · Reply
LewisDaKat
LewisDaKat Aug. 17 at 7:30 PM
$URGN UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC https://marketwirenews.com/stock/urgn/news/urogen-submits-nda-for-ugn-103-an-investigational-tr-5828805966855917.html?utm_source=stocktwits
0 · Reply
Pukkaa56
Pukkaa56 Aug. 17 at 6:27 PM
$URGN Up to $50
0 · Reply
Mogeyman
Mogeyman Aug. 17 at 1:50 PM
$URGN Let's see how this goes. With how big the 2Q ER was, I imagine 3Q is going to be even better.
0 · Reply
andrew_rovo
andrew_rovo Aug. 17 at 1:24 PM
$URGN https://investors.urogen.com/news-releases/news-release-details/urogen-submits-nda-ugn-103-investigational-treatment-recurrent
0 · Reply
Mogeyman
Mogeyman Aug. 14 at 8:39 PM
$URGN Will be loading up next week when funds clear. Not waiting for a dip.
0 · Reply
TheBehavioralTrader
TheBehavioralTrader Aug. 12 at 11:00 PM
$MGNI $PAYS $URGN All three of these symbols have the same behavioral pattern all three were alerted today for members StockreversalsPremium.com
0 · Reply
Mogeyman
Mogeyman Aug. 12 at 8:52 PM
$URGN This thing is a monster 2Q ER was awesome, I imagine 3Q will be another banger.
0 · Reply
WAJeff
WAJeff Aug. 12 at 7:17 PM
$URGN 49.67 52 week high
0 · Reply
MaverikIT
MaverikIT Aug. 12 at 6:59 PM
$ATRC $NRIX $URGN new 52wk$ today
0 · Reply
Latest News on URGN
UroGen Pharma submits UGN-103 NDA to FDA

2026-08-17T12:11:24.000Z - 2 days ago

UroGen Pharma submits UGN-103 NDA to FDA

URGN


UroGen Pharma Earnings Call Transcript: Q2 2026

Aug 5, 2026, 10:00 AM EDT - 13 days ago

UroGen Pharma Earnings Call Transcript: Q2 2026


UroGen Pharma Earnings release: Q2 2026

Aug 5, 2026, 10:00 AM EDT - 13 days ago

UroGen Pharma Earnings release: Q2 2026


UroGen Pharma Quarterly report: Q2 2026

Aug 5, 2026, 10:00 AM EDT - 13 days ago

UroGen Pharma Quarterly report: Q2 2026


UroGen Pharma Slides: Corporate presentation

Aug 4, 2026, 7:00 AM EDT - 15 days ago

UroGen Pharma Slides: Corporate presentation


UroGen Pharma Transcript: AGM 2026

Jun 22, 2026, 10:00 AM EDT - 2 months ago

UroGen Pharma Transcript: AGM 2026


UroGen Pharma reports month results from UTOPIA trial

2026-05-15T15:46:42.000Z - 3 months ago

UroGen Pharma reports month results from UTOPIA trial

URGN


UroGen Pharma presents 36-month ENVISION trial data

2026-05-13T14:22:11.000Z - 3 months ago

UroGen Pharma presents 36-month ENVISION trial data

URGN


UroGen Pharma assumed with a Buy at Ladenburg

2026-05-11T15:30:55.000Z - 3 months ago

UroGen Pharma assumed with a Buy at Ladenburg

URGN


UroGen Pharma to Present at Upcoming Investor Conferences

May 7, 2026, 8:00 AM EDT - 3 months ago

UroGen Pharma to Present at Upcoming Investor Conferences

URGN


UroGen Pharma reports Q1 EPS (47c), consensus (36c)

2026-05-07T03:46:46.000Z - 3 months ago

UroGen Pharma reports Q1 EPS (47c), consensus (36c)

URGN


UroGen Pharma Earnings Call Transcript: Q1 2026

May 6, 2026, 10:00 AM EDT - 3 months ago

UroGen Pharma Earnings Call Transcript: Q1 2026


UroGen Pharma Earnings release: Q1 2026

May 6, 2026, 10:00 AM EDT - 3 months ago

UroGen Pharma Earnings release: Q1 2026


UroGen Pharma Quarterly report: Q1 2026

May 6, 2026, 10:00 AM EDT - 3 months ago

UroGen Pharma Quarterly report: Q1 2026


UroGen Pharma Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

UroGen Pharma Proxy statement: Proxy filing


UroGen Pharma Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

UroGen Pharma Proxy statement: Proxy filing


UroGen Pharma initiated with a Buy at Jefferies

2026-04-09T20:26:32.000Z - 4 months ago

UroGen Pharma initiated with a Buy at Jefferies

URGN


UroGen Pharma Earnings Call Transcript: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Earnings Call Transcript: Q4 2025


UroGen Pharma Annual report: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Annual report: Q4 2025


UroGen Pharma Earnings release: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Earnings release: Q4 2025


UroGen Pharma Annual report: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Annual report: Q4 2025


UroGen Pharma reports Q4 EPS (54c), consensus (51c)

2026-03-02T13:06:31.000Z - 6 months ago

UroGen Pharma reports Q4 EPS (54c), consensus (51c)

URGN


UroGen Pharma Slides: Corporate presentation

Mar 2, 2026, 7:00 AM EST - 6 months ago

UroGen Pharma Slides: Corporate presentation


UroGen Pharma Earnings Call Transcript: Q3 2025

Nov 6, 2025, 10:00 AM EST - 10 months ago

UroGen Pharma Earnings Call Transcript: Q3 2025


UroGen Pharma Quarterly report: Q3 2025

Nov 6, 2025, 10:00 AM EST - 10 months ago

UroGen Pharma Quarterly report: Q3 2025


UroGen Pharma Earnings release: Q3 2025

Nov 6, 2025, 10:00 AM EST - 10 months ago

UroGen Pharma Earnings release: Q3 2025


UroGen Pharma Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 10 months ago

UroGen Pharma Slides: Corporate Presentation


UroGen Pharma Transcript: AGM 2025

Aug 26, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Transcript: AGM 2025


UroGen Pharma Earnings Call Transcript: Q2 2025

Aug 7, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Earnings Call Transcript: Q2 2025


UroGen Pharma Quarterly report: Q2 2025

Aug 7, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Quarterly report: Q2 2025


UroGen Pharma Earnings release: Q2 2025

Aug 7, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Earnings release: Q2 2025


UroGen Pharma Slides: Corporate Presentation

Aug 7, 2025, 7:00 AM EDT - 1 year ago

UroGen Pharma Slides: Corporate Presentation


UroGen Pharma Proxy statement: Proxy Filing

Jul 15, 2025, 8:00 AM EDT - 1 year ago

UroGen Pharma Proxy statement: Proxy Filing


UroGen Pharma Slides: Corporate Presentation

Jun 17, 2025, 7:00 AM EDT - 1 year ago

UroGen Pharma Slides: Corporate Presentation


UroGen Pharma Transcript: Study Update

Jun 13, 2025, 8:30 AM EDT - 1 year ago

UroGen Pharma Transcript: Study Update


UroGen Pharma Press release: Study Update

Jun 13, 2025, 8:30 AM EDT - 1 year ago

UroGen Pharma Press release: Study Update


UroGen Pharma Slides: Study Update

Jun 13, 2025, 8:30 AM EDT - 1 year ago

UroGen Pharma Slides: Study Update


US FDA approves Urogen's bladder cancer drug

Jun 12, 2025, 12:48 PM EDT - 1 year ago

US FDA approves Urogen's bladder cancer drug

URGN


ivocsev
ivocsev Aug. 18 at 11:51 AM
1 · Reply
LewisDaKat
LewisDaKat Aug. 17 at 7:30 PM
$URGN UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC https://marketwirenews.com/stock/urgn/news/urogen-submits-nda-for-ugn-103-an-investigational-tr-5828805966855917.html?utm_source=stocktwits
0 · Reply
Pukkaa56
Pukkaa56 Aug. 17 at 6:27 PM
$URGN Up to $50
0 · Reply
Mogeyman
Mogeyman Aug. 17 at 1:50 PM
$URGN Let's see how this goes. With how big the 2Q ER was, I imagine 3Q is going to be even better.
0 · Reply
andrew_rovo
andrew_rovo Aug. 17 at 1:24 PM
$URGN https://investors.urogen.com/news-releases/news-release-details/urogen-submits-nda-ugn-103-investigational-treatment-recurrent
0 · Reply
Mogeyman
Mogeyman Aug. 14 at 8:39 PM
$URGN Will be loading up next week when funds clear. Not waiting for a dip.
0 · Reply
TheBehavioralTrader
TheBehavioralTrader Aug. 12 at 11:00 PM
$MGNI $PAYS $URGN All three of these symbols have the same behavioral pattern all three were alerted today for members StockreversalsPremium.com
0 · Reply
Mogeyman
Mogeyman Aug. 12 at 8:52 PM
$URGN This thing is a monster 2Q ER was awesome, I imagine 3Q will be another banger.
0 · Reply
WAJeff
WAJeff Aug. 12 at 7:17 PM
$URGN 49.67 52 week high
0 · Reply
MaverikIT
MaverikIT Aug. 12 at 6:59 PM
$ATRC $NRIX $URGN new 52wk$ today
0 · Reply
MaverikIT
MaverikIT Aug. 12 at 2:16 PM
$AEHR $URGN @BustaCapital @Jblack500 @cynicaloptimist @IsabellaDC @WAJeff @No_Face_character
0 · Reply
chickenboy
chickenboy Aug. 11 at 10:12 PM
$URGN Short interest has plunged to 4.589M shares as of 7/31/26, almost a 20% drop since the 7/15/26 report. Wishing I had bought more shares in the $30's. GLTA.
1 · Reply
Merlintrader
Merlintrader Aug. 10 at 1:55 PM
UroGen Pharma ($URGN) Stock Hub 2026: ZUSDURI At US$50.4 Million, Revenue Nearly Tripled And A US$132 Million Shareholders’ Deficit https://www.merlintrader.com/urogen-pharma-urgn-stock-hub/
0 · Reply
Mogeyman
Mogeyman Aug. 9 at 3:41 PM
$URGN Nothing but up from here.
1 · Reply
_ProfessorGamma
_ProfessorGamma Aug. 7 at 6:26 PM
$URGN it's time to step it up
1 · Reply
Mogeyman
Mogeyman Aug. 7 at 6:12 PM
$URGN WHAT DID I SAY, BABY!? $75 EOY. BO probably next.
0 · Reply
ivocsev
ivocsev Aug. 7 at 3:19 PM
0 · Reply
WAJeff
WAJeff Aug. 7 at 2:39 PM
$URGN Impressive
1 · Reply
chickenboy
chickenboy Aug. 6 at 8:28 PM
$URGN I decided to get back into with with a couple of thousand shares. I listened to the call this morning...I really liked the Zusduri revenue growth but expected some guidance to be given on it. Jelmyto rev came in lite (they didn't seem to care) and would have liked more detail on how 2026 operating expenses guidance increased 20M to 270M. I don't see a bo in the near future but would like to see near $60/share by end of 2027. GLTA.
1 · Reply
topstockalerts
topstockalerts Aug. 5 at 8:03 PM
$URGN this has that “don’t overthink it” look.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Aug. 5 at 6:51 PM
$URGN Zusduri sales by quarter post launch v $DAWN Ojemda. The graphs excludes Jelmyto sales that have averaged $20-$22MM per quarter. DAWN was acquired for an EV of $2.15B. This is not investment advice. We're genuinely curious if URGN investors believe Zusduri is worth more in a M&A exit than DAWN because Zusduri is outselling Ojemda? We'll post updated URGN analyst projections v DAWN management projections within the next few weeks. Again this is not investment advice. Remember URGN is obligated to forward a financier a royalty on product sales that may affect an exit valuation (we have no idea). $XBI $IBB $NBI
1 · Reply
Braindead83
Braindead83 Aug. 5 at 5:32 PM
$URGN short, way overvalued. Bad management. Annualized revenue is not attractive for M&A. No reason for for this price, albeit a solid product. This is just chasing. Should be reading at $30
2 · Reply